Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
Alimera Sciences (NASDAQ: ALIM) has appointed Dr. David Dyer as chief retina specialist, enhancing its leadership team. Dr. Dyer brings significant experience from his practice in Kansas City and is expected to contribute valuable insights in retina care. His role aims to drive Alimera's vision of being a leader in retinal treatments, particularly focusing on the ILUVIEN product. Additionally, Dr. Dyer's involvement in the Phase 4 NEW DAY Study highlights Alimera's commitment to advancing treatment options. This expansion signals Alimera's intent to strengthen its market position and broaden its global reach.
- Appointment of Dr. David Dyer as chief retina specialist is expected to enhance leadership.
- Dr. Dyer's extensive experience is anticipated to provide insights into retinal treatment.
- Focus on ILUVIEN product aims to improve market positioning and growth.
- Participation in the Phase 4 NEW DAY Study indicates commitment to innovative treatments.
- None.
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri.
“I am very excited that Dr. Dyer is joining our team in this newly created position as he brings the insights of a seasoned practicing retina specialist, and accomplished business owner to Alimera,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “Dr. Dyer’s intricate retina knowledge, his years of practice experience, and his understanding of novel technologies will play an instrumental role in achieving our vision of being the place to be in retina, focused solely on the needs of retina specialists and their patients.”
“The opportunity to work with the Alimera team to develop the corporate vision into a reality and emphasize ILUVIEN’s ability to provide long-term control of recurrence of disease brings continued significant potential in both the U.S. and international markets,” said Dr. Dyer “Additionally, the Phase 4 NEW DAY Study is an exciting and needed comparison of long-term steroid versus anti-VEGF treatment. The company continues to grow its international footprint, creating a platform for potential future products.”
Dr. Dyer founded Retina Associates, LLC in 1999, one of the most well-established and advanced practices devoted to diagnosing and treating diseases of the retina, macula, and vitreous in the Greater Kansas City area and the surrounding communities. Dr. Dyer also founded TreVia Digital Health, LLC, a health care company that provides technology-enabled services, including digital diabetic retinopathy screenings, for the diagnosis and prevention of diabetic retinopathy complications and iTronix Systems, LLC a medical device development company.
A board certified retina specialist, Dr. Dyer received his undergraduate degree from George Mason University and received his medical degree from the University of Kansas School of Medicine. He completed his ophthalmology residency at Storm Eye Institute/Medical University of South Carolina and completed his retina fellowships at The Wilmer Ophthalmological Institute/The Johns Hopkins University, Baltimore, Maryland and Rush- Presbyterian St. Luke’s Medical Center, Chicago, Illinois.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s long-term vision, including the possibility of international growth and new products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to the ability of the Company to turn its long-term vision into reality, to grow internationally, and to successfully bring additional products to market, as well as the other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2020 and Alimera’s Quarterly Report on Form 10-Q for the three months ended March 31, 2021 which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at http://www.sec.gov.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
FAQ
What is the significance of Dr. David Dyer's appointment at Alimera Sciences?
What does Dr. Dyer plan to achieve as chief retina specialist?
How might Dr. Dyer's role impact Alimera's future product offerings?
What is the Phase 4 NEW DAY Study mentioned in the press release?
